 NEW YORK, May 24, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system CNS disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 22,258,066 shares of its common stock, at a price to the public of 3.10 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to Seelos from this offering are expected to be approximately 64.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. 